Paradromics

Paradromics is creating a future where direct data interfaces with the brain unlock technology solutions to unmet medical challenges. Our platform–and the massive brain data it accesses–has broad potential for therapeutic and diagnostic application to countless neurological or brain-related disorders.

Paradromics Inc., an Austin-based medical technology company, today announced participation in the 2022 Built with Biology Global Synthetic Biology conference, April 12-14 in Oakland, California. (Built with Biology was formerly known as SynBioBeta.) This year’s conference features a day of neurotechnology programming on April 12, which was organized in cooperation with Paradromics. Paradromics CEO and Founder, Matt Angle, PhD, is moderating a panel entitled “Can Neurotech Transform Mental Health?” featuring panelists Renee Ryan, CEO of Cala Health, Brian Pepin, CEO of Rune Labs, and Juan-Pablo Mas, Partner, at Action Potential VC. Dr. Angle is a panelist for the session titled “Engineering the Mind”, a fireside chat that will explore the vast potential and implications of neurotechnology. About Paradromics The brain is a data organ; it needs a data interface. At Paradromics, we’re enabling a future where direct data interfaces with the brain unlock technology solutions to unmet medical challenges. A revolutionary leap beyond today’s lab-confined brain-computer interfaces (BCI), our Connexus® Direct Data Interface (DDI) collects an unprecedented number of individual neural signals with a fully-implantable device designed for long-term daily service. Our first clinical application is an assistive communication device for patients who’ve lost the physical ability to speak or type. The Connexus DDI platform—and the vast brain data it accesses–has boundless potential for future applications, from enabling people with sensory and motor impairment to treating neuropsychiatric disorders. Paradromics, Inc. is an Austin-based medical technology company. Founded in 2015, we have raised $38M in venture funding and received $18M in non-dilutive public funding.